The Tokyo Foundation for Policy Research


The Tokyo Foundation for Policy Research


中島 啓/Kei Nakashima


Kei Nakashima

Last updated : April 19, 2024

Director, Department of Pulmonology, Kameda Medical Center

Areas of Expertise
  • Clinical Epidemiology
  • Clinical Medicine
  • Medical Education
  • Respiratory Infections
  • Epidemiological Research

To provide the highest level of medical care, I dedicated to enhance clinical practice, education, and research at Kameda Medical Center. I graduated from Kyushu University School of Medicine in 2006. Following my graduation, I completed my initial training at St. Mary’s Hospital and internal medicine training at the Saiseikai Fukuoka General Hospital before joining the Department of Pulmonology, Kameda Medical Center. In September 2023, I became the Director of the Department of Pulmonology and concurrently serve as the Chairman of Internal Medicine at Kameda Medical Center. I hold a Doctor of Medicine degree and work as a researcher in the Department of Public Health, the Graduate School of Medicine, Osaka Metropolitan University. My research focuses on respiratory infections and vaccines. I also serve as an Associate Editor for Human Vaccines & Immunotherapeutics and a member of the Editorial Board for Scientific Reports.

Research Program
Human resource development for data-driven healthcare policy

Select Publications

  • Ohmura SI, Matsui H, Miyamoto T, Shichi D, Masui T, Ichijo K, Homma Y, Fujioka H, Nagai T, Nakashima K. Comparison of the outcomes of Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics. Respir Investig. 2024 Mar 6;62(3):377-383.

  • Yamamoto S, Matsui H, Fujioka H, Homma Y, Kubota N, Otsuki A, Ito H, Sagara H, Nakashima K. Predictors of improvement of radial-endobronchial ultrasonography findings from "adjacent to" to "within" in endobronchial ultrasonography using a guide sheath: a retrospective cohort study. J Thorac Dis. 2024 Jan 30;16(1):264-272.

  • Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Masuda S, Osawa R, Hosokawa N, Nakashima K, Kamura H, Imura H, Inoue H, Matsuzaka S, Sugimoto Y, Kuwamitsu O, Motohashi I, Morikawa T, Oda R, Hoshina Y, Matono T, Teshigahara O, Sando E, Asami S, Kudo S, Akizuki N, Muto Y, Hayakawa T, Kishaba T, Ohara Y, Kubo Y, Suzuki M, Morimoto K. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Rev Vaccines. 2024 Jan-Dec;23(1):213-225.

  • Otsuki A, Inoshima N, Tochigi K, Ito H, Nakashima K. Efficacy and safety of 40 mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study. Thorac Cancer. 2024 Mar;15(7):570-574.

  • Nakashima K, Homma Y, Taniguchi J, Kubota N, Otsuki A, Ito H, Otsuka Y, Kondo K, Ohfuji S, Fukushima W, Hirota Y. Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study. J Infect Chemother. 2023 Nov;29(11):1038-1045.

  • Nagai T, Matsui H, Fujioka H, Homma Y, Otsuki A, Ito H, Ohmura S, Miyamoto T, Shichi D, Tomohisa W, Otsuka Y, Nakashima K. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Non-HIV-Infected Patients: A Multicenter, Retrospective Observational Cohort Study. Chest. 2023 Aug 11:S0012-3692(23)05269-8.

  • Taniguchi J, Matsui H, Nagai T, Otsuki A, Ito H, Sugimura H, Nakashima K. Association between intrapleural urokinase monotherapy and treatment failure in patients with pleural infection: a retrospective cohort study. BMC Pulm Med. 2023 Jul 21;23(1):273.

  • Yoshioka T, Shinozaki T, Hori A, Okawa S, Nakashima K, Tabuchi T. Association between exposure to secondhand aerosol from heated tobacco products and respiratory symptoms among current non-smokers in Japan: a cross-sectional study. BMJ Open. 2023 Mar 7;13(3):e065322.

  • Nakashima K, Ishida M, Matsui H, Yoshida C, Nagai T, Shiraga M, Nakaoka H, Otsuka Y, Nakagama Y, Kaku N, Nitahara Y, Kido Y, Hirota Y. Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study. Hum Vaccin Immunother. 2022 Nov 30;18(6):2140549.

  • Nakashima K, Suzuki K, Aoshima M, Murabata M, Kondo K, Ohfuji S, Fukushima W, Maeda A, Hirota Y; Pneumonia in Elderly People Study Group. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan. Vaccine. 2022 Nov 2;40(46):6589-6598.

  • Taniguchi J, Nakashima K, Matsui H, Nagai T, Otsuki A, Ito H, Sugimura H. The relationship between chest tube position in the thoracic cavity and treatment failure in patients with pleural infection: a retrospective cohort study. BMC Pulm Med. 2022 Sep 20;22(1):358.

  • Nakashima K, Misawa M, Otsuki A, Narita K, Otsuka Y, Matsue K, Aoshima M. Efficacy and Safety of Endobronchial Ultrasonography with a Guide-sheath for Acute Pulmonary Lesions in Patients with Haematological Diseases. Intern Med. 2022;61(5):623-632.

  • Taniguchi J, Nakashima K, Matsui H, Watari T, Otsuki A, Ito H, Otsuka Y. Low cut-off value of serum (1,3)-beta-D-glucan for the diagnosis of Pneumocystis pneumonia in non-HIV patients: a retrospective cohort study. BMC Infect Dis. 2021 Nov 29;21(1):1200.

  • Nemoto M, Nakashima K, Noma S, Matsue Y, Yoshida K, Matsui H, Shiraishi A, Ishifuji T, Morimoto K, Ariyoshi K, Aoshima M. Prognostic value of chest computed tomography in community-acquired pneumonia patients. ERJ Open Res. 2020 Nov 23;6(4):00079-2020.

  • Suzuki K, Kondo K, Washio M, Nakashima K, Kan S, Imai S, Yoshimura K, Ota C, Ohfuji S, Fukushima W, Hirota Y. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study. Hum Vaccin Immunother. 2019;15(9):2171-2177.

  • Nakashima K, Aoshima M, Ohfuji S, Yamawaki S, Nemoto M, Hasegawa S, Noma S, Misawa M, Hosokawa N, Yaegashi M, Otsuka Y. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial. Hum Vaccin Immunother. 2018;14(8):1923-1930.

  • Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, Misawa M, Otsuka Y, Motojima S. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study. J Microbiol Immunol Infect. 2018 Dec;51(6):810-820.

  • Imai K, Petigara T, Kohn MA, Nakashima K, Aoshima M, Shito A, Kanazu S. Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases. BMJ Open. 2018 Mar 2;8(3):e018553.

  • Nakashima K, Aoshima M, Ohfuji S, Suzuki K, Katsurada M, Katsurada N, Misawa M, Otsuka Y, Kondo K, Hirota Y. Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Hum Vaccin Immunother. 2017 Mar 4;13(3):543-550.

  • Nakashima K, Aoshima M, Ohkuni Y, Hoshino E, Hashimoto K, Otsuka Y. Loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia in HIV-uninfected immunocompromised patients with pulmonary infiltrates. J Infect Chemother. 2014 Dec;20(12):757-61.

Contact This Expert



Click on the link below to contact an expert or submit a question.